Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 1;160(5):495-501.
doi: 10.1001/jamadermatol.2023.6158.

Lived Experiences and Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma

Ayisha N Mahama  1 , Courtney N Haller  1 , Jocelyn Labrada  1   2 , Christie I Idiong  3 , Alex B Haynes  4   5 , Elizabeth A Jacobs  6   7 , Joel Tsevat  2   8   9 , Michael P Pignone  2   5 , Adewole S Adamson  1   2   5   10
Affiliations

Lived Experiences and Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma

Ayisha N Mahama et al. JAMA Dermatol. .

Abstract

Importance: Most of the rapid increase in cutaneous melanoma incidence in the US has been localized disease that is treated surgically and is associated with high survival rates. However, little is known about the psychological well-being of survivors in the US.

Objective: To explore the lived experiences and fear of cancer recurrence among survivors of localized cutaneous melanoma.

Design, setting, and participants: This was a qualitative and survey-based study that used semistructured interviews and the Fear of Cancer Recurrence Inventory short form (FCRI-SF) survey tool with participants recruited from an academic dermatology practice affiliated with the University of Texas, Austin. Interviews were completed via telephone or in person from August 2021 to September 2022. Each of the 9 items in the FCRI-SF was rated on a 5-point Likert scale, scored from 0 to 4, with a maximum possible score of 36 points. Data analyses were performed from February 2022 to June 2023.

Main outcomes and measures: Semistructured interviews were analyzed for themes and subthemes associated with the lived experiences of survivors of cutaneous melanoma. The FCRI-SF scores were tabulated, with scores of 13 or greater identifying potential cases of clinically significant fear of cancer recurrence.

Results: In all, 51 participants (mean [SD] age, 49.5 [11.7] years; 34 [67%] female and 17 [33%] male) with a history of localized melanoma (stage 0-IIA) completed the interview and survey. Among them, 17 (33%) had survived a diagnosis of stage 0 melanoma, and the remainder, at least 1 invasive melanoma diagnosis (stage I-IIA). Semistructured interviews revealed several themes: (1) emotions surrounding follow-up appointments, (2) intensity of melanoma surveillance, (3) lifestyle changes regarding sun exposure, and (4) thoughts about life and death. Thirty-eight of 51 participants had an FCRI-SF score above the threshold for clinical fear of cancer recurrence.

Conclusions and relevance: This qualitative and survey-based study found that despite having an excellent prognosis, some survivors of localized melanoma, even those who had stage 0, have high rates of fear of cancer recurrence and intense survivorship experiences that affect their psychological well-being.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure.
Figure.. Score Distribution on the Fear of Cancer Recurrence (FCR) Inventory−Short Form (N = 51)
The yellow area shows participants who reached a threshold of 13 or greater (high sensitivity) and the beige area shows participants who reached a threshold of 16 or greater (high specificity).
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. doi: 10.3322/caac.21763 - DOI - PubMed
    1. Cancer Stat Facts . Melanoma of the Skin. Accessed May 15, 2023. https://seer.cancer.gov/statfacts/html/melan.html
    1. Welch HG, Mazer BL, Adamson AS. The rapid rise in cutaneous melanoma diagnoses. N Engl J Med. 2021;384(1):72-79. doi: 10.1056/NEJMsb2019760 - DOI - PubMed
    1. Marcadis AR, Marti JL, Ehdaie B, Hakimi AA, Davies L, Morris LGT. Characterizing relative and disease-specific survival in early-stage cancers. JAMA Intern Med. 2020;180(3):461-463. doi: 10.1001/jamainternmed.2019.6120 - DOI - PMC - PubMed
    1. Patel VR, Roberson ML, Pignone MP, Adamson AS. Risk of mortality after a diagnosis of melanoma in situ. JAMA Dermatol. 2023;159(7):703-710. doi: 10.1001/jamadermatol.2023.1494 - DOI - PMC - PubMed

Publication types